Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PHVSBullishIndustry Newsnews

High materiality8/10

RAPIDe-3 results strengthen Pharvaris' case for first oral HAE therapy

Oct 8, 2026, 6:42 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive Phase 3 results and publication plus regulatory submissions create near-term upside risk/reward; potential first-mover oral HAE therapy could drive multiple expansion if approvals occur, though delay/regulatory risk could cap upside.

AI summary

What happened, with direct paths to the underlying reporting

Pharvaris reports RAPIDe-3 shows deucrictibant IR delivers rapid HAE attack relief, with 1.28-hour onset and 11.95-hour resolution. The Lancet publication plus pending FDA and EMA reviews create near-term catalysts, with a 2027 PDUFA target. If approved, it would be the first oral bradykinin B2 receptor antagonist for on-demand HAE, potentially shifting treatment standards.

RAPIDe-3: onset 1.28h; complete resolution 11.95h.
All endpoints met with high statistical significance across 11 secondary endpoints.
Lancet publication boosts global visibility for deucrictibant IR.
FDA NDA and EMA MAA under review; PDUFA date 2027-04-23.
RAPIDe-2 open-label extension and EAP ongoing; orphan designation granted.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

RAPIDe-3 results strengthen Pharvaris' case for first oral HAE therapy

Pharvaris' oral HAE therapy hits primary endpoint in pivotal trial

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows